Next Article in Journal
Application-Oriented Bulk Cryopreservation of Human iPSCs in Cryo Bags Followed by Direct Inoculation in Scalable Suspension Bioreactors for Expansion and Neural Differentiation
Previous Article in Journal
Liquid Biopsy in Neurological Diseases
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Perspective

Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer—Looking Back and Forward

1
The First Department of Oncologic Gynecology and Gynecology, Medical University of Lublin, 20-081 Lublin, Poland
2
Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA
Cells 2023, 12(14), 1912; https://doi.org/10.3390/cells12141912
Submission received: 4 June 2023 / Revised: 15 July 2023 / Accepted: 20 July 2023 / Published: 22 July 2023
(This article belongs to the Section Cellular Immunology)

Abstract

Myeloid-derived suppressor cells (MDSCs) play a significant role in the immune system and have been extensively studied in cancer. MDSCs are a heterogeneous population of myeloid cells that accumulate in the tumor microenvironment. Consequently, the high abundance of these cells often leads to immunosuppression, tumor growth, treatment failure, and poor prognosis. Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female genital tract. Currently, there is a lack of effective clinical strategies for the treatment of ovarian cancer. Although several studies underline the negative role of human MDSCs in ovarian cancer, this topic is still understudied. The works on MDSCs are summarized here, along with an explanation of why focusing on these cells would be a promising approach for treating ovarian cancer patients.
Keywords: myeloid-derived suppressor cells; MDSCs; ovarian cancer; immunotherapy; CAR-M; TME; therapy resistance myeloid-derived suppressor cells; MDSCs; ovarian cancer; immunotherapy; CAR-M; TME; therapy resistance

Share and Cite

MDPI and ACS Style

Okła, K. Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer—Looking Back and Forward. Cells 2023, 12, 1912. https://doi.org/10.3390/cells12141912

AMA Style

Okła K. Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer—Looking Back and Forward. Cells. 2023; 12(14):1912. https://doi.org/10.3390/cells12141912

Chicago/Turabian Style

Okła, Karolina. 2023. "Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer—Looking Back and Forward" Cells 12, no. 14: 1912. https://doi.org/10.3390/cells12141912

APA Style

Okła, K. (2023). Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer—Looking Back and Forward. Cells, 12(14), 1912. https://doi.org/10.3390/cells12141912

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop